Cutiss AG

Automation Program



funded by the European Union:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 830454

Full Title: Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.
EU Officer: Mr. Chrysafis Argyros

From 2018-10-01 to 2020-09-30

Funding scheme: H2020-EIC-SMEINST-2018-2020


funded by Innosuisse & in collaboration with CSEM
This project has also received funding by Swiss Innovation Promotion Agency Innosuisse in collaboration with CSEM. More Information
Cutiss AG

Automation Program

funded by the European Union:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 830454

Full Title: Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.
EU Officer: Mr. Chrysafis Argyros

From 2018-10-01 to 2020-09-30
Funding scheme: H2020-EIC-SMEINST-2018-2020
 
funded by Innosuisse & in collaboration with CSEM
This project has also received funding by Swiss Innovation Promotion Agency Innosuisse in collaboration with CSEM. More Information

Horizon 2020 (H2020) is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness.

CUTISS AG has been awarded an SME Instrument Phase 2 grant of €2.5 million under grant agreement No. 830454

Within the denovoSkin™ project, CUTISS will set up and validate the SkinFactory 2.0 – an automated production process to improve the scalability of denovoSkin™. SkinFactory 2.0 will be put to commercial use once Market Authorisation is granted. In the meantime, it will be used to produce skin for patients involved in the clinical trials.

The SME Instrument is a programme under the Horizon 2020 framework run by the EASME, the European Executive Agency for Small and Medium-sized Enterprises. CUTISS already secured a Phase 1 SME Instrument grant in 2018. The Phase 2 project continues the work started in Phase 1, contributing the financial resources needed to advance the market readiness.

The denovoSkin™ project will be executed from 2018 to 2020 with activities broken down into 4 Work Packages:

  1. WP1 Automation of Production Process. The automation of the process will be done by a specialised automation company to be selected by the end of 2018, supported by us.
  2. WP2 Integrated system validation
  3. WP3 Exploitation and communication of project results
  4. WP4 Project management.

Our EU Officer is Mr. Chrysafis Argyros
Linkedin Profile

The project is running in collaboration with the following partners:
CSEM – funded by Innosuisse Grant 
Zühlke – empowering ideas
HTSS – Europe’s premier medtech market access
Renesol – Kathi Mujynya
Luzzatto & Luzzatto patent Attorneys

Team members involved in the project:

Daniela Marino, CEO and Co-founder of CUTISS
She received her M.Sc. in Biotechnologies from the University of Milan in 2005 and her Ph.D. from the Institute of Pharmacological Sciences of ETH Zurich in 2009. During her postdoctoral studies at the Tissue Biology Research Unit of the University Children’s Hospital in Zurich, she specialized in tissue engineering of skin, and also gained expertise in project management, product development, clinical trials and regulatory affairs.
• Coordinator/Project Manager (WP4)
• Project Coordination Board (WP4)
• Communication and Exploitation (WP3)

Fabienne Hartmann-Fritsch, CCO and Co-founder of CUTISS
She received her M.Sc. in Microbiology and Immunology from the ETH Zurich in 2008 and her Ph.D. in Biology from the University of Zurich in 2013. During her postdoctoral studies at the Tissue Biology Research Unit of the University Children’s Hospital Zurich she specialized on GMP-production of human skin grafts as well as on clinical trial management and regulatory affairs.
• Technical Manager (WP4)
• Project Coordination Board (WP4)

Vincent Ronfard, Chief Innovation Officer
He holds a PhD in Cell Biology. Vincent has more than 28 years of experience in the field of Regenerative Medicine. He started his career at the Blood Transfusion Center (Lille, France) where he developed a fibrin substrate to transplant human keratinocytes to treat burns. From 2010 to 2015 he was Vice-President of Research and Development at HealthPoint Biothrerapeutics.
• Automation of production process (WP1)
• Integrated system Validation (WP2)
• Project Coordination Board (WP4)
• Exploitation and communication (WP3)

Silvia Stüdeli, Operations Specialist
She received her M.Sc. in Interdisciplinary Sciences from the ETH Zurich in 2014. At the Tissue Biology Research Unit of the University Children’s Hospital Zurich Silvia gained broad expertise in tissue engineering of skin. She also has profound experience as Clinical Project Manager from her work in cancer research.
• Integrated system Validation (WP2)

Laurent Barnes, Senior Innovation Scientist
Laurent Barnes has more than 8 years’ experience in skin biology and dermatology. He joined CUTISS in October 2017 to develop the automation of Production.
• Automation of the production process (WP1)
• Integrated system validation (WP2)

Jackie Vuistiner, Management Assistant
Experience in Office and Event Management with the task of ensuring a systematic and sufficient exploitation of the project results during the lifetime of the project, managed by the the Exploitation manager.
• Exploitation and communication (WP3)

Claude Holenstein, Process Developer
PhD in Biomechanics to be involved in the automation and validation tasks managed by Silvia Stüdeli.
• Automation of the production process (WP1)
• Integrated system validation (WP2)

 

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

This website uses cookies to ensure you get the best experience on our website.